Evidence map›Paper›PMID 38136304›Full record

ArticleCancers2023

Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.

Carlo Signorelli, Mario Giovanni Chilelli, Diana Giannarelli, Michele Basso, Maria Alessandra Calegari, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 1 country.

Carlo SignorelliMedical Oncology Unit, Belcolle Hospital, ASL Viterbo, 01100 Viterbo, Italy.ORCID 0000-0002-0960-9563
Mario Giovanni ChilelliMedical Oncology Unit, Belcolle Hospital, ASL Viterbo, 01100 Viterbo, Italy.
Diana GiannarelliBiostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy.
Michele BassoUnit of Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy.
Maria Alessandra CalegariUnit of Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy.
Annunziato AngheloneUnit of Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy.
Jessica LucchettiDivision of Medical Oncology, Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
Alessandro MinelliDivision of Medical Oncology, Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
Lorenzo AngottiDivision of Medical Oncology, Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
Ina Valeria ZurloMedical Oncology, "Vito Fazzi" Hospital, 73100 Lecce, Italy.
Marta SchirripaMedical Oncology Unit, Belcolle Hospital, ASL Viterbo, 01100 Viterbo, Italy.
Cristina MorelliMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.
Emanuela Dell'AquilaMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-7258-1364
Antonella CosimatiMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Donatello GemmaMedical Oncology Unit, ASL Frosinone, 03039 Sora (FR), Italy.
Marta RibelliMedical Oncology Unit, Isola Tiberina Hospital-Gemelli Isola, 00186 Rome, Italy.
Alessandra EmilianiMedical Oncology Unit, Isola Tiberina Hospital-Gemelli Isola, 00186 Rome, Italy.
Domenico Cristiano CorsiMedical Oncology Unit, Isola Tiberina Hospital-Gemelli Isola, 00186 Rome, Italy.ORCID 0000-0002-5017-6704
Giulia ArriviDepartment of Clinical and Molecular Medicine, Oncology Unit, Sant' Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy.ORCID 0000-0003-0541-415X
Federica MazzucaDepartment of Clinical and Molecular Medicine, Oncology Unit, Sant' Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy.
Federica ZorattoMedical Oncology Unit, ASL Latina, 04100 Latina, Italy.
Maria Grazia MorandiMedical Oncology Unit, San Camillo de Lellis Hospital, ASL Rieti, 02100 Rieti, Italy.
Fiorenza SantamariaUOC Oncology A, Policlinico Umberto I, 00185 Rome, Italy.ORCID 0000-0002-1214-9342
Rosa SaltarelliUOC Oncology, San Giovanni Evangelista Hospital, ASL RM5, 00019 Tivoli (RM), Italy.
Enzo Maria RuggeriMedical Oncology Unit, Belcolle Hospital, ASL Viterbo, 01100 Viterbo, Italy.
Agostino Gemelli University Polyclinic · ITOspedale di Belcolle · ITCampus Bio Medico University Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITSapienza University of Rome · ITAccademia di Belle Arti di Frosinone · ITOspedale Vito Fazzi · ITPoliclinico Umberto I · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

first drug treatment durationmetastatic colorectal cancerreal-world studyregorafenibsequential treatmentthird-line therapytrifluridine/tipiracil

Identifiers

PMID38136304
PMCPMC10741389
OpenAlexW4389480495

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.